Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Abstract

Background The systemic immune-inflammation index (SII) is a novel biomarker to predict the prognosis of some malignant tumors based on neutrophil, platelet, and lymphocyte counts. Evidence is scarce about the prognostic value of SII for prostate cancer patients. This systematic review and meta-analysis was conducted to explore the prognostic value of the SII in prostate cancer. Methods The PubMed, Embase, Web of Science, and Cochrane Library (CENTRAL) databases were searched to determine eligible studies from inception to August 15, 2022. Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to pool the results. Statistical analyses were conducted by using Stata 17.0 software. Results A total of 12 studies with 8083 patients were included. The quantitative synthesis showed that a high SII was related to poor overall survival (OS) (HR = 1.44, 95% CI 1.23–1.69, p < 0.001). Furthermore, a subgroup analysis showed that a high SII was associated with poor OS in the groups of any ethnicity, tumor type, and cutoff value. An increased SII was also associated with inferior progression-free survival (PFS) (HR = 1.80, 95% CI 1.27–2.56, p = 0.001). In the subgroup analysis, a high SII value was related to poor PFS in Asian patients (HR = 4.03, 95% CI 1.07–15.17, p = 0.04) and a cutoff value > 580 (HR = 1.19, 95% CI 1.04–1.36, p = 0.01). Conclusion Based on the current evidence, a high pretreatment SII may be associated with poor OS and PFS. The SII may serve as an important prognostic indicator in patients with prostate cancer. More rigorously designed studies are needed to explore the SII and the prognosis of prostate cancer.

Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617

“…In addition, high SII was also associated with low PFS (HR = 1.80, 95% CI: 1.27-2.56, P = .001). [31] In the present study, SII was observed as a prognostic marker for OS (HR: 2.17, 95% CI: 1.09-4.32, P = .027) but was not predictive for PFS (P = .531). However, PIV was not significantly associated both with survival and progression (P = .069 and .908, respectively).…”

“…[12,15,30] Based on a meta-analysis of 12 prostate cancer studies, high SII is associated with reduced OS (HR = 1.44, 95% CI: 1.23–1.69, P < .001). [31] In the subgroup analysis, it was found that this relationship did not change according to the cutoff value, ethnicity and tumor type. In addition, high SII was also associated with low PFS (HR = 1.80, 95% CI: 1.27–2.56, P = .001).…”

Depressive Symptoms, Systemic Inflammation, and Survival Among Patients With Head and Neck Cancer

“…58 New research should also extend to other tumor types given that inflammation is a risk factor for progression [59][60][61][62] and survival across prostate, ovarian, breast, and head and neck cancers. 18,[63][64][65][66][67] Our tests for potentially confounding variables revealed that the direct association of SII with survival was not robust when T classification was entered into the model. It is possible that worsening inflammation concomitant with tumor progression may introduce covariance sufficient to cloud the relationships between inflammation, T classification, and survival.…”

Association between preoperative systemic immune inflammation index and postoperative sepsis in patients with intestinal obstruction: A retrospective observational cohort study

“…The SII was associated with the prognosis of patients with hepatocellular carcinoma after curative resection in the beginning 29 . In general, SII has been found to have predictive value for the prognosis of various tumors 30–32 . Meanwhile, most studies have shown that a higher SII is associated with the occurrence and poor prognosis of sepsis 21,33 .…”